공시 • Aug 12
BiVictriX Therapeutics plc Proposes Voluntary Cancellation of Admission of Ordinary Shares to Trading on AIM BiVictriX Therapeutics plc announced the proposed cancellation of the admission of its ordinary shares of £0.01 each ("Ordinary Shares") from trading on AIM (the "Cancellation") and the re-registration of the Company as a private limited company (the "Re-registration"). A circular ("Circular") will be sent to Shareholders, setting out the background to and reasons for the Cancellation and the Re-registration. The Company is seeking Shareholder approval for the Cancellation and Re-registration at a general meeting, which has been convened for 11:30 a.m. on 29 August 2024 at the Company's registered office, Mereside Alderley Park, Alderley Edge, Manchester SK10 4TG ("General Meeting"), notice of which is included in the Circular. The Company is also seeking Shareholder approval at the General Meeting for the adoption of new articles of association (the "New Articles") to be effective on the Re-registration. If the Cancellation Resolution is passed at the General Meeting, it is anticipated that the Cancellation will become effective at 7:00 a.m. on 11 September 2024. The Cancellation Resolution is conditional, pursuant to Rule 41 of the AIM Rules, upon the approval of Shareholders holding not less than 75 per cent. of the votes cast by Shareholders (whether present in person or by proxy) at the General Meeting. The Company has received irrevocable undertakings from DBW Investments, Robert Keith, Alderley Park Ventures Limited, BioCity Investments Limited, Alden AS and those Directors who are also Shareholders,as set out below, representing in aggregate approximately 42.5 per cent. of the Company's issued share capital, to vote in favour of the Resolutions set out in the Circular. New Risk • Aug 02
New major risk - Financial position The company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -UK£2.1m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£2.1m free cash flow). Earnings have declined by 29% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (UK£10.7m market cap, or US$13.7m). 공시 • Jun 27
BiVictriX Therapeutics Plc, Annual General Meeting, Jul 24, 2024 BiVictriX Therapeutics Plc, Annual General Meeting, Jul 24, 2024. Location: the office of bivictrix therapeutics plc, mereside alderley park, alderley edge, macclesfield, england, sk10 4tg, United Kingdom 공시 • Jun 09
BiVictriX Therapeutics plc Receives Grants to Accelerate Solid Tumour Targeting ADC Pipeline from Innovate UK BiVictriX Therapeutics Plc announced it has been awarded a grant for £0.37 million from Innovate UK. The grant will facilitate accelerating the preclinical development of BiVictriX's second pipeline product, BVX002, a novel bispecific ADC targeting the treatment of ovarian cancer. In line with the Company's strategy to seek non-dilutive capital to progress R&D, the Innovate UK grant will enable BiVictriX to accelerate its efforts tofurther advance BVX002, including preclinical studies and preparation for the selection of a clinical lead candidate. The funds will be used on R&D activities to enhance the value of BVX002 and BiVictriX's expertise in the solid tumour setting. The Innovate UK research and development project (funded for 18 months) will consist of two primary elements: selection of the optimal linker/payload and therapeutic format combination, followed by assessment of in vivo efficacy, selectivity and safety to move the best bispecific ADC molecules towards nomination of a clinical lead candidate for BVX002. New Risk • Jun 07
New major risk - Revenue and earnings growth Earnings have declined by 40% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 40% per year over the past 5 years. Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (UK£9.90m market cap, or US$12.7m). New Risk • Apr 07
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (25% increase in shares outstanding). Market cap is less than US$100m (UK£9.28m market cap, or US$11.7m). 
